Jenner & Block's Collins on forces driving pharma M&A - The Deal Pipeline (SAMPLE CONTENT: NEED AN ID?)
Subscriber Content Preview | Request a free trialSearch  
  Go

Healthcare

Print  |  Share  |  Reprint

Jenner & Block's Collins on forces driving pharma M&A

by David Marcus  |  Published May 8, 2012 at 11:52 AM


The expiration of blockbuster drug patents and the melding of generic and branded drug makers has become one of the driving forces for M&A, according to Jenner & Block LLP's Kevin Collins, who spoke with The Deal Pipeline's David Marcus at Northwestern Law's 32nd Annual Ray Garrett Jr. Corporate and Securities Law Institute. - George White 

Share:
Tags: Jenner & Block | Kevin Collins | M&A | pharmaceuticals

Free preview

This is only a preview of The Deal's sophisticated coverage. Explore the real-time intelligence as researched and reported on by our team of financial journalists with a license to The Deal Pipeline. Click here for more information.

Meet the journalists

David Marcus

Senior Writer: Law Firms & Legal Issues

Contact



Movers & Shakers

Launch Movers and shakers slideshow

NBGI Private Equity appointed food and drinks industry veteran Tim Kelly as a senior adviser. For other updates launch today's Movers & shakers slideshow.

Video

Shop, then chop

Blackstone Real Estate and DDR divide 46 shopping centers in a $1.46 billion deal. More video

Sectors